Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This study will determine whether Ataciguat (HMR1766) is well-tolerated in patients with mild
to moderate calcific aortic valve stenosis. The primary focus of these studies will be on
changes in blood pressure and orthostatic tolerance (i.e., ability to stand up without
passing out), and determining whether treatment with Ataciguat results in significant
reductions in blood pressure in this patient population.
Phase:
Phase 1
Details
Lead Sponsor:
Jordan D. Miller, Ph.D.
Collaborators:
National Center for Advancing Translational Science (NCATS) National Center for Research Resources (NCRR) Sanofi-Synthelabo